ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1665545
The Effect of BRAFV600E Mutation on Radioiodine Therapy in Patients with Papillary Thyroid Carcinoma: a Meta-analysis and Systematic Review
Provisionally accepted
- Shanghai Changzheng Hospital, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective The BRAFV600E mutation is one of the most common genetic alterations in papillary thyroid cancer (PTC) and is widely recognized as a factor of poor prognosis. Radioactive iodine (RAI) therapy is recommended after thyroidectomy for patients with high-risk level PTC or distant metastatic PTC. However, the association between BRAFV600E mutation and RAI refractoriness remains controversial and requires additional investigation. This meta-analysis was conducted to evaluate the impact of BRAFV600E mutation on the curative effect of RAI therapy. Materials and Methods Electronic searches for relevant studies were performed in the databases of PubMed, EMBASE, and the Science Citation Index databases, with publication date after January 2005. The 131I uptakes status, response to RAI therapy and recurrence of RAI therapy were extracted and compared using meta-analysis. Results We included 14 eligible studies incorporating 2890 PTC patients, of which 1966 were patients with BRAFV600E mutation. The pooled analysis indicated that BRAFV600E mutation was strongly associated with the loss of iodine avidity (P=0.0003) in PTC patients, especially in recurrent individuals (P<0.0001). However, BRAFV600E mutation had no significant association on the clinical response or recurrence rate of RAI therapy (P=0.27 and P=0.29, respectively). Conclusion This meta-analysis confirmed the role of BRAFV600E mutation in deterioration of the ability of RAI uptake but provided insufficient evidence to demonstrate that BRAFV600E mutation might impact the clinical response and recurrence after postsurgical RAI therapy for PTC patients.
Keywords: Papillary thyroid carcinoma, radioactive iodine refractoriness, BRAFV600E mutation, Therapeutic response, Meta-analysis
Received: 14 Jul 2025; Accepted: 08 Sep 2025.
Copyright: © 2025 Wang, Cen, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bin Wang, Shanghai Changzheng Hospital, Shanghai, China
Wei Zhang, Shanghai Changzheng Hospital, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.